AbbVie Says Botox Business Recovering But Allergan Drags Down Q2 Financials

 
• By Joseph Haas

AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.

Team_Puzzle
The merger complete, AbbVie unveiled its combined earnings with Allergan

More from Earnings

More from Business